MedImmune to Present Four Flu Abstracts at the Influenza Vaccines for the World Conference
GAITHERSBURG, Md., Oct. 9, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced today it will present four abstracts at the Influenza Vaccines for the World (IVW) International Conference at the Palacio de Congresos de Valencia, Valencia, Spain, October 9-12, 2012. These abstracts advance the body of existing data and knowledge surrounding influenza vaccination, highlighting MedImmune's continued leadership in helping to improve patient health.
MedImmune abstracts to be presented at IVW regarding influenza include:
- Impact of intranasal live attenuated influenza vaccine on societal and economic burden of influenza in European/Israeli children 2-17 years of age. Ambrose C.S., et al. Oral Presentation: October 10, 2012, Time: 2:00 PM 2:20 PM, Session 3: Influenza Burden & Pandemic Session
- Does intranasal live attenuated influenza vaccine reduce all-cause acute otitis media in children? Heikkinen T, et al. Oral Presentation: October 11, 2012, Time: 2:40 PM 3:00 PM, Session 7: Implementation, Safety & Immunogenicity
- Do Influenza Illness Symptoms Differ Among Vaccinated and Unvaccinated Children? Ambrose C.S., et al. Poster Session, October 9, 2012, Poster 101
- A Postlicensure Evaluation of the Safety of Intranasal Live Attenuated Influenza Vaccine in Children 2 to 17 Years of Age. Ambrose C.S., et al. Poster Session, October 9, 2012, Poster 102
Additional information about the 2012 IVW conference can be found at http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=6&Itemid=7
MedImmune, the global biologics arm of AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com.